Table 2.
Association between clinicopathologic features and IVR in UTUC.
| Characteristic | With IVR | Without IVR | p value |
|---|---|---|---|
| N=58 | N=162 | ||
| Age (years) | 67.5 (40-84) | 67.5 (38-86) | 0.84 |
| Sex | 0.51 | ||
| Male | 28 (48.3%) | 70 (43.2%) | |
| Female | 30 (51.7%) | 92 (56.8%) | |
| BMI | 24.31 (16.42-31.55) | 24.61 (16.44-40.00) | 0.37 |
| History of hypertension | 0.19 | ||
| No | 25 (43.1%) | 86 (53.1%) | |
| Yes | 33 (56.9%) | 76 (46.9%) | |
| History of diabetes | 0.42 | ||
| No | 48 (82.8%) | 126 (77.8%) | |
| Yes | 10 (17.2%) | 36 (22.2%) | |
| Laterality | 0.15 | ||
| Left | 27 (46.6%) | 93 (57.4%) | |
| Right | 31 (53.4%) | 69 (42.6%) | |
| Location | 0.72 | ||
| Renal pelvis | 24 (41.4%) | 73 (45.1%) | |
| Ureter | 30 (51.7%) | 81 (50.0%) | |
| Both | 4(6.9%) | 8(5.0%) | |
| Multifocality | 0.01 | ||
| Single | 39 (67.2%) | 135 (83.3%) | |
| Multiple | 19 (32.8%) | 27 (16.7%) | |
| Pathologic stage | 0.08 | ||
| pT1 | 25 (43.1%) | 91 (56.2%) | |
| pT2 | 19 (32.8%) | 33 (20.4%) | |
| pT3 | 10 (17.2%) | 34 (21.0%) | |
| pT4 | 4 (6.9%) | 4 (2.5%) | |
| Lymph node status | 0.68 | ||
| pN0/pNx | 57 (98.3%) | 156 (96.3%) | |
| pN+ | 1 (1.7%) | 6 (3.7%) | |
| Tumor grade | 0.42 | ||
| Low | 4 (6.9%) | 17 (10.5%) | |
| High | 54 (93.1%) | 145 (89.5%) | |
| Tumor size (cm) | 3.0 (0.4-9.5) | 2.5 (0.2-8.5) | 0.24 |
| Margin status | 0.02 | ||
| Negative | 53 (91.4%) | 160 (98.8%) | |
| Positive | 5 (8.6%) | 2 (1.2%) | |
| Urine pathology | <0.01 | ||
| Negative | 11 (19.0%) | 84 (51.9%) | |
| Tumor cell | 21 (36.2%) | 13 (8.0%) | |
| Atypical | 26 (44.8%) | 65 (40.1%) | |
| Hydronephrosis | 0.02 | ||
| ≤2cm | 29 (50.0%) | 109 (67.3%) | |
| >2cm | 29 (50.0%) | 53 (32.7%) | |
| Adjuvant chemotherapy | <0.01 | ||
| No | 45 (77.6%) | 67 (41.4%) | |
| Yes | 13 (22.4%) | 95 (58.6%) | |
| Creatinine (μmol/L) | 0.22 | ||
| ≤106 | 43 (74.1%) | 106 (65.4%) | |
| >106 | 15 (25.9%) | 56 (34.6%) | |
| NLR | 4.14 (1.00-13.74) | 4.03 (1.61-10.14) | 0.39 |
| LMR | 1.52 (0.32-3.00) | 1.6 (0.48-3.42) | 0.35 |
| URS | 0.14 | ||
| No URS | 17 (29.3%) | 69 (42.6%) | |
| 1-Session | 36 (62.1%) | 76 (46.9%) | |
| 2-Session | 5 (8.6%) | 17 (10.5%) | |
| Survival time (months) | 39 (4-143) | 42 (2-143) | 0.76 |
UTUC, upper urinary tract cancer; IVR: intravesical recurrence; URS, ureteroscopy; BMI, body mass index; NLR, neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio